Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -26.14% is 48% above its 2-year average of -50.44%, near the high end of its 2-year range (-99.12%–-26.14%).
As of the fiscal period ended Tuesday, June 30, 2026. 56.91% above its 12-month average of -60.65%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -26.14%.
RETURN ON EQUITY (ROE)
-26.14%
RETURN ON EQUITY (ROE) AVG TTM
-60.65%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+56.91%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+37.79%
vs the sector median at left
Artiva Biotherapeutics, Inc.
Market Cap
$355.43M
Return on Equity (ROE)
-26.14%
TTM Avg
-60.65%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$355.36M
Return on Equity (ROE)
10.07%
TTM Avg
9.56%
3Y Avg
8.63%
5Y Avg
13.79%
Market Cap
$353.88M
Return on Equity (ROE)
-62.56%
TTM Avg
-108.31%
3Y Avg
-79.06%
5Y Avg
-57.33%
Market Cap
$353.00M
Return on Equity (ROE)
N/A
TTM Avg
-12.63%
3Y Avg
-14.73%
5Y Avg
14.28%
Market Cap
$352.67M
Return on Equity (ROE)
N/A
TTM Avg
187.63%
3Y Avg
25.60%
5Y Avg
-9.96%
Market Cap
$359.53M
Return on Equity (ROE)
-7.66%
TTM Avg
-10.18%
3Y Avg
260.20%
5Y Avg
144.75%
Market Cap
$349.70M
Return on Equity (ROE)
-200.64%
TTM Avg
-134.16%
3Y Avg
-101.12%
5Y Avg
-54.69%
Market Cap
$361.64M
Return on Equity (ROE)
N/A
TTM Avg
-589.37%
3Y Avg
-290.01%
5Y Avg
-205.39%
Market Cap
$346.73M
Return on Equity (ROE)
-1229.58%
TTM Avg
464.26%
3Y Avg
-581.37%
5Y Avg
-581.37%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | $355.43M | -26.14% | -60.65% | N/A | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 10.07% | 9.56% | 8.63% | 13.79% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | -62.56% | -108.31% | -79.06% | -57.33% |
| Embecta Corp. (EMBC)vs › | $353.00M | N/A | -12.63% | -14.73% | 14.28% |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | 187.63% | 25.60% | -9.96% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | -7.66% | -10.18% | 260.20% | 144.75% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | -200.64% | -134.16% | -101.12% | -54.69% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | -589.37% | -290.01% | -205.39% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | -1229.58% | 464.26% | -581.37% | -581.37% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | -29.98% | -145.74% | -129.76% | -105.96% |
ROE
-26.1%
ROA
-24.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -26.14% |
| 2026-03-31 | -99.12% |
| 2025-12-31 | -76.26% |
| 2025-09-30 | -55.96% |
| 2025-06-30 | -45.79% |
| 2025-03-31 | -38.42% |
| 2024-12-31 | -31.34% |
| 2024-09-30 | -30.49% |
